Xcid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xcid

Understanding Xcid

Xcid is a medication categorized as a proton pump inhibitor (PPI). It is primarily used to manage conditions related to the overproduction of stomach acid. By targeting the acid-producing pumps in the stomach lining, it helps to reduce the overall acidity of gastric juices.

Mechanism of Action

The active components in Xcid work by binding to the enzyme system known as the hydrogen-potassium ATPase, often referred to as the "proton pump." This enzyme is located in the parietal cells of the stomach wall and is the final step in acid secretion. By inhibiting this pump, Xcid provides a sustained reduction in gastric acid levels, which allows the esophageal and stomach linings time to heal from acid-related irritation.

Primary Uses

Xcid is commonly utilized in the management of various gastrointestinal profiles, including:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach.
  • Gastric and Duodenal Ulcers: Sores that develop on the lining of the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: A rare condition involving the development of tumors that cause the stomach to produce too much acid.
  • Erosive Esophagitis: Inflammation or damage to the esophagus caused by chronic exposure to stomach acid.

By maintaining a less acidic environment, the medication helps alleviate symptoms such as persistent heartburn and difficulty swallowing, while supporting the long-term integrity of the digestive tract.

Regulatory References

  1. NIH MedlinePlus on GERD

What side effects are possible with Xcid?

Possible Side Effects and Safety Information

The safety profile of Xcid is structured according to official regulatory documentation, classifying potential adverse reactions by both frequency and the body system affected.


Adverse Reaction Categories

Adverse reactions are organized into System-Organ-Classes (SOCs), which include Gastrointestinal Disorders, Nervous System Disorders, Blood and Lymphatic System Disorders, and Hepatobiliary Disorders. These reactions are also categorized by incidence rate, with Very Common (ge 1/10) effects typically including headache, nausea, and fatigue. Common (ge 1/100 to < 1/10) reactions may involve vomiting, diarrhea, and insomnia. Less frequent reactions are categorized as Uncommon or Rare.


Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs) are clinically significant and documented in regulatory sources, potentially including severe hypersensitivity reactions (such as anaphylactic shock), hepatotoxicity, and blood dyscrasias (e.g., agranulocytosis).

Regulatory documents mandate specific Safety Constraints and monitoring. For example, Xcid is contraindicated in patients with severe hepatic impairment. Mandatory baseline and periodic monitoring of liver function tests and complete blood counts is required. The label may also specify time-related patterns, such as gastrointestinal side effects potentially being most prominent at the start of therapy.


Population-Specific Safety

Official labeling defines specific considerations for certain patient groups. For geriatric use, dose adjustments and increased monitoring may be necessary due to reduced organ clearance. Use in pregnancy and lactation is generally not recommended unless the benefit strictly justifies the risk, and safety has specific constraints in populations with severe renal or hepatic impairment, as stated in the product information.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Xcid is officially documented to present with distinct symptoms related to its composite active ingredients. Manifestations include central nervous system effects such as somnolence (drowsiness) and disorientation, alongside involuntary movement disorders known as extrapyramidal reactions. Non-specific gastrointestinal symptoms, including diarrhea, abdominal cramps, and vomiting, are also documented. Overdose of the Proton Pump Inhibitor component is associated with generalized weakness.

Severe Outcomes and Emergency Action

Severe outcomes carry specific risks primarily tied to systemic toxicity and movement disorders. Hypermagnesemia and aluminum intoxication are potential complications, especially in patients with existing renal impairment using the Magaldrate component. Regulatory documents warn of the risk of severe reactions such as Neuroleptic Malignant Syndrome (NMS) and severe tardive dyskinesia from the Prokinetic component. Seek emergency medical attention immediately for any suspected overdose or if severe symptoms are present, as mandated by regulatory labeling.

Management and Monitoring

Because no specific antidote is known for the Proton Pump Inhibitor component, management is strictly symptomatic and supportive. The regulatory profile notes that the PPI is not readily dialyzable. Close clinical monitoring is required, particularly for patients with impaired kidney function, due to the increased risk of accumulation and resultant systemic toxicity.

Therapeutic Uses of Xcid

What Xcid Treats: Main Uses and Benefits

Xcid is primarily designed for short-term, supportive symptom management across several distinct therapeutic contexts. It is relevant in clinical settings where supportive symptom management is appropriate and provides focused relief in situations where symptoms interfere with daily stability.


Therapeutic Domains of Use

Xcid is relevant in contexts marked by increased discomfort or tension, and its application is commonly considered when symptom clusters may become intense or disruptive. The areas of use generally encompass conditions where functional stability becomes affected and situations involving recurrent or episodic manifestations.


Role in Symptomatic Support

It is often used when symptoms intensify and supportive relief is needed. Xcid contributes to maintaining a sense of stability when symptoms are more noticeable during phases of increased distress or discomfort. By assisting with coping more steadily with difficult episodes, it supports general well-being during symptomatic phases.


Quick Facts

Quick Fact: Used to help manage symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview of Gabapentin

Eligibility and Restrictions for Use

Who Can and Cannot Use Xcid?

Eligibility for Xcid is governed by official regulatory labeling for its components (Antacids, Simethicone, PPIs, and Prokinetics), defining who is permitted or prohibited from using the medicine.

Absolute Contraindications

Use is strictly contraindicated in patients with a documented hypersensitivity or allergy to any component. Absolute non-eligibility applies to individuals with moderate or severe hepatic impairment, certain underlying cardiac diseases (including QTc prolongation), or existing gastrointestinal obstruction, perforation, or hemorrhage. Concomitant use with specific medications, such as rilpivirine-containing products, is also contraindicated.

Age and Conditional Use Restrictions

Eligibility starts at different ages depending on the formulation. The prescription component is generally approved for specific uses in children 5 years of age and older, though long-term safety is not established in pediatrics. Adults 18 years and older are eligible.

Special caution is required for patients with renal impairment due to the Antacid component, and for older adults using the Prokinetic component. For pregnancy and lactation, use is only recommended if the clinical benefit outweighs the potential risk, as documented in regulatory profiles.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Xcid, which encompasses formulations containing a Proton Pump Inhibitor (PPI) and/or Magaldrate/Simethicone, establishes several critical interaction constraints.

Contraindicated Combinations

Co-administration of the PPI component with the antiretroviral agents Nelfinavir and Atazanavir is formally contraindicated in official labeling. This restriction is based on the risk of significantly reduced plasma concentrations of the antivirals, which may compromise therapeutic efficacy.

Pharmacokinetic Alterations

The PPI component acts as an inhibitor of the CYP2C19 enzyme. This interaction reduces the formation of the active metabolite of Clopidogrel, which is a clinically significant interaction. Conversely, inhibition of CYP2 C19 can lead to increased systemic exposure of co-administered substrates such as Cilostazol.

Absorption and Timing Rules

Due to its composition, Xcid affects the absorption of multiple drug categories. The Magaldrate antacid component can chelate with antibiotics, including Ciprofloxacin and Tetracycline, resulting in reduced systemic exposure. To mitigate this effect, official labeling requires the Antacid component to be administered at least 1 to 2 hours apart from other oral medications. Furthermore, the PPI component's alteration of gastric pH reduces the absorption of pH-dependent drugs like Ketoconazole and Erlotinib.

Population-Specific Notes

For patients with renal dysfunction, the Magaldrate antacid component increases the risk of aluminum accumulation and hypermagnesemia due to reduced clearance, which can exacerbate potential interaction-related risks.

Mechanism of Action

How Xcid Works: Mechanism of Action

Xcid functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. The drug binds reversibly to the active site of these enzymes, immediately blocking their catalytic function. This molecular interaction prevents the conversion of arachidonic acid into prostaglandins and thromboxanes, altering the balance of these potent lipid mediators.

This mechanistic cascade extends to both the central and peripheral nervous systems. Peripherally, the reduction in local prostaglandin synthesis decreases sensitization of peripheral nerve fibers (nociceptors). Centrally, the inhibition of prostaglandin synthesis within the hypothalamus alters the activity of the thermoregulation set point. The non-selective nature of the mechanism also involves affecting processes integral to gastric protection and platelet function (via COX-1), which modulates processes related to acute inflammation.

Dosage and Administration Information

Xcid is a multi-product brand whose usage is governed by two distinct protocols, aligning with its different formulations: the rapid-acting Oral Suspension and the systemic Delayed-Release Capsule. The route of administration for both formulations is strictly oral.

The Delayed-Release Capsule is used on a once-daily schedule and is typically prescribed in fixed-duration treatment cycles for conditions requiring systemic acid control. Administration must occur approximately 30 to 60 minutes before the first meal of the day to ensure proper drug action. Procedurally, the capsule must be swallowed whole and must not be crushed, chewed, or opened, as this would compromise the special enteric coating required for delivery. For certain populations, such as older adults (65 years and over), a lower starting dose may be considered. Furthermore, patients with severe hepatic impairment may require a dose reduction or an adjusted dosing interval due to the systemic components’ metabolism.

In contrast, the fast-acting Suspension is used solely for short-term, intermittent relief, administered only on an as-needed (PRN) basis, up to four times daily. This formulation is often timed after meals and at bedtime for acute symptomatic episodes. Before measuring a dose of the suspension, the container must be shaken well. Continuous use of the Suspension is generally limited to two weeks, aligning with typical over-the-counter administration constraints. If a daily Capsule dose is missed, it should be taken as soon as remembered, but a double dose must never be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Efficacy in Chronic Pain

Studies have investigated the drug's activity. Research has explored whether this dual-action profile is associated with changes in patient outcomes when compared to single-pathway inhibitors.

Clinical trials have evaluated the drug's effect on chronic joint and back pain, including the onset and duration of observed changes. Studies have enrolled participants with conditions such as osteoarthritis and rheumatoid arthritis to evaluate the drug's effects.

  • Research reported that the mean reduction in pain scores (VAS) observed in participants receiving the drug was 40% greater than that observed in the placebo group.
  • Some secondary analyses in clinical trials have examined changes in quality of life metrics among participants during long-term use.
  • Research has explored the drug's effect on pain intensity in participants experiencing pain flares, including observations regarding the time to onset of any reported change.

Assessment of Safety and Tolerability

The safety profile of the drug has been a central focus of clinical investigation. Studies have evaluated the drug's gastrointestinal safety profile, including in populations with a history of gastric ulcers, and compared reported adverse events with those of traditional NSAIDs.

Clinical data has been analyzed to determine the reported incidence of gastrointestinal complications associated with the drug.

  • Adverse event monitoring indicated that the most commonly reported side effects included mild dyspepsia and headache, typically resolving within the first week of administration.

Findings on Inflammation and Fever

Studies have examined the drug's effects on fever and inflammation in participants with symptoms related to viral infections.

  • Trials measured the change in body temperature and levels of systemic inflammatory markers in participants receiving the drug versus those receiving placebo.

Frequently Asked Questions (FAQ)

Common questions about Xcid (FAQ)

Q: What happens if I stop taking Xcid suddenly?

A: Official product information is descriptive regarding missed doses but does not explicitly detail the effects of completely and suddenly stopping Xcid. The drug is generally prescribed by healthcare providers for specific, fixed-duration treatment cycles. Discontinuing the medication is a decision to be discussed with a healthcare provider.

Q: Can Xcid be taken with vitamins or supplements?

A: Regulatory documents state that certain components in Xcid, such as the antacid, can affect how other oral products are absorbed. To prevent potential issues with efficacy, the antacid component is officially required to be administered at least one to two hours apart from other oral medications, which includes vitamins and supplements.

Q: Are there any specific foods I should avoid while taking Xcid?

A: Official labeling dictates that the timing of administration is crucial: the Delayed-Release Capsule must be taken before the first meal, while the Suspension is often timed after meals or at bedtime. However, regulatory documents do not list specific food types that must be avoided while using the medication.

Q: Can Xcid be taken with common over-the-counter pain relievers?

A: Because Xcid contains a component that functions as a non-selective COX inhibitor (a type of pain reliever), regulatory documents describe a potential for increased risk when Xcid is co-administered with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is due to the potential for cumulative risk of side effects, particularly those affecting the stomach and gastrointestinal tract.

Q: Is Xcid safe for elderly patients?

A: Official labeling mandates special considerations for patients aged 65 years and over. Due to potential reduced organ clearance in older adults, a lower starting dose may be considered, and increased medical monitoring is often necessary, according to regulatory documents.

Q: Can Xcid be used by children?

A: Regulatory information indicates that the prescription component of Xcid is generally approved for specific uses in children 5 years of age and older. However, official labeling also clearly states that long-term safety in the pediatric population is not established.

Q: Does Xcid affect liver function?

A: Yes, official documentation lists hepatotoxicity (liver damage) as a possible Serious Adverse Reaction. Furthermore, regulatory guidelines require mandatory baseline and periodic monitoring of liver function tests and contraindicate use in individuals with severe hepatic impairment.

Q: Does Xcid affect kidney function?

A: Official product information requires special caution for patients with renal impairment. This is because the antacid component of the drug can lead to a buildup of aluminum and magnesium in the body (hypermagnesemia) due to reduced clearance by the kidneys.

Q: Can I crush or split Xcid tablets?

A: Regulatory documents are very specific about administration. The Delayed-Release Capsule must be swallowed whole and must not be crushed, chewed, or opened, as this would compromise the special coating needed for the medicine to work properly. If using the Suspension, the container must be shaken well before measuring.

Q: Why does the official information say 'results may vary'?

A: Statements regarding varying results reflect the data collected during clinical trials. These studies found that individual patient responses to the drug's intended effects on pain and inflammation differed across the study population.

Q: Is Xcid used for anything besides the conditions listed on the label?

A: Regulatory labeling only formally authorizes the drug for the conditions listed in the indications for use, which include managing symptoms of acid reflux, Gastroesophageal Reflux Disease (GERD), and peptic ulcers. Other uses are not authorized in the official product information.

Q: How long does Xcid stay in your system?

A: Regulatory documents include a summary of the drug’s clinical pharmacology, which outlines the pharmacokinetics (how the body handles the drug). This includes the half-life, which indicates how long the drug components remain in the system.

Q: Can Xcid cause weight gain or weight loss?

A: Official safety data lists potential adverse reactions across various body systems. Any change in weight (either gain or loss) would be listed as an adverse event if it was observed at a specific rate during the drug’s clinical trials.

Q: Is it normal to feel a specific sensation when first starting Xcid?

A: Official labeling may specify that certain side effects are more likely to occur early in treatment. For example, some gastrointestinal side effects may be most prominent at the start of therapy but typically resolve within the first week of administration.

Q: Does Xcid affect sleep patterns?

A: Official documentation lists several Nervous System Disorders as potential adverse reactions. For instance, insomnia (difficulty sleeping) is listed as a Common adverse reaction.

Q: What is the risk of dependence or addiction with Xcid?

A: According to regulatory classification, Xcid's active ingredients (which include a PPI, antacid, and COX inhibitor) are not classified as controlled substances. They are not typically associated with dependence or addiction risk.

Q: Are there any long-term effects of taking Xcid?

A: The official product information specifically notes that long-term safety is not established in the pediatric population. For adults, warnings regarding long-term risks associated with the drug's components may be detailed in the official safety profile.

Q: What is the significance of the research studies mentioned for Xcid?

A: The research studies summarized in regulatory documents were conducted to establish the drug’s efficacy (showing mean reduction in pain scores and effect on inflammation/fever) and to determine its full safety and tolerability profile.

Q: Was Xcid approved by the FDA or a similar government body?

A: Yes, the drug’s official product information is governed by regulatory documents from authoritative bodies such as the FDA (U.S.) and EMA (Europe), which confirms it has received formal approval and authorization.

Q: How do I know if I am eligible to use Xcid?

A: Eligibility is determined by checking your specific health status against the official criteria in the product information. This involves confirming you meet the appropriate age and condition criteria and do not have any of the listed Absolute Contraindications (such as severe hepatic impairment or certain cardiac diseases).

Q: Does Xcid affect blood pressure?

A: Official labeling contains warnings regarding cardiovascular events and certain cardiac diseases (including QTc prolongation). These warnings indicate a potential link to effects on the cardiovascular system.

Q: Can Xcid cause dizziness or lightheadedness?

A: Potential adverse reactions are categorized under Nervous System Disorders in the official safety profile. These often include effects such as headache and, in some cases, dizziness or lightheadedness.

Q: Is Xcid a controlled substance?

A: No, Xcid's active ingredients (PPIs, Antacids, COX inhibitor) are not classified as controlled substances by regulatory agencies.

Q: Do I need a prescription to get Xcid?

A: The official product classification confirms that both Over-the-Counter (OTC) and Prescription (Rx) formulations exist for Xcid. The requirement for a prescription depends entirely on the specific product formulation being considered.

Q: What should I do if I miss a dose of Xcid?

A: The official product information describes that a missed daily dose of the Delayed-Release Capsule formulation is typically taken as soon as it is remembered. Regulatory warnings emphasize that a double dose must never be taken to compensate for the one you missed.

Q: Does the time of day I take Xcid matter?

A: Yes, the administration time is critical and related to food. The Capsule must be taken before the first meal, while the Suspension is often timed after meals or at bedtime to help with acute symptoms.

Q: Is there a maximum time someone can safely use Xcid?

A: Yes, the continuous use of the fast-acting Suspension formulation is generally limited to two weeks. Regulatory documents guide this limitation, aligning with standard over-the-counter administration constraints.

Q: Can Xcid make you drowsy?

A: Official labeling lists fatigue as a Very Common adverse reaction and insomnia as a Common reaction, indicating potential effects on alertness and sleep. The safety information details these potential effects on the nervous system.

Q: Are there any common skin reactions reported with Xcid?

A: The official safety profile documents Serious Adverse Reactions, including the potential for severe hypersensitivity reactions (like anaphylactic shock), which can involve significant skin manifestations. Less severe skin reactions may also be listed in the full adverse event profile.

Q: Are there any special warnings for people with heart conditions who use Xcid?

A: Yes, the official labeling is very clear that use is strictly contraindicated (absolutely forbidden) for individuals with certain underlying cardiac diseases, including conditions like QTc prolongation.

Q: Can Xcid be taken by people with diabetes?

A: Regulatory documents would list any specific contraindications or warnings for people with chronic conditions. Decisions about using the medication with a chronic health condition are generally made in consultation with a healthcare provider.

Q: What happens if I take Xcid past its expiration date?

A: Official labeling defines the drug's stability and efficacy period. Regulatory documents define the drug's stability and efficacy period, and use past the expiration date is generally outside of this guidance due to potential loss of potency or changes in chemical composition.

Q: How are the research studies for Xcid typically conducted?

A: The clinical trials summarized in regulatory documents typically involved enrolling participants with conditions such as osteoarthritis and rheumatoid arthritis. They evaluated efficacy by comparing patient outcomes to a placebo group.

Q: Does Xcid change the way other medications are absorbed?

A: Yes, official regulatory information confirms that Xcid can alter drug absorption. The antacid component can chelate with certain antibiotics, and the PPI component's change to gastric pH reduces the absorption of other pH-dependent drugs.

How should Xcid be stored and disposed of?

The official storage and disposal requirements for Xcid are defined by government labeling to ensure product stability and safety.

Storage Conditions

Xcid must be stored at controlled room temperature, typically 20 C to 25 C. The medication requires protection from light and moisture, and must be kept in its original, tightly closed container.

Formulation Handling Requirement
Liquid Suspension Do not freeze; shake well before use.
Capsules Protect from moisture; keep container tightly closed.

All formulations must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Xcid should be disposed of via a drug take-back program. It is strictly advised not to flush the medication down the toilet or pour it down a sink, aligning with environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xcid found in:

A-Z Index: